Jim Strattman

@CAgovernor sacbee.com/news/politics-…

I'm offering $50,000 rewards to anyone providing information that helps crack unsolved crimes in California. If you know something, it is your duty to come forward to give victims and their loved ones justice. Every case matters, every victim matters, and California is determined to secure accountability.

The level of risk for @US_FDA is unreal. Arm ‘s Length replaced by hand’s up my ass. $QURE

@alphavestcap Can the 850 day old dc vax L maa application be moved along toward the finish line ? prnewswire.com/news-releases/… CLAUDE: DOES DR ANNALISA JENKINS CURRENTLY HAVE AN ADVISORY ROLE WTH THE MHRA, OR DOES SHE HAVE RELATIONSHIPS WITH MHRA EMPLOYEES WHEREBY SHE COULD INFLUENCE THEIR DECISION MAKING ? Claude responded: Based on my research from the previous search, I can give you a clear answer:Based on my research from the previous search, I can give you a clear answer: No formal MHRA advisory role. Dr. Jenkins does not appear in any MHRA advisory body, committee, or board. The March 2025 MHRA Board Declarations of Interest document — which lists all declared relationships — contains no mention of her. Her regulatory advisory role is with the FDA, not the MHRA. She sits on the Science Board to the U.S. Food & Drug Administration, which is a completely separate organisation. On potential informal influence: This is harder to establish or rule out from public records, but a few things are worth noting: She is a prominent figure in UK life sciences and has publicly commented on MHRA leadership and strategy, including praising the appointment of Lawrence Tallon as MHRA CEO in 2025. This reflects engagement as an industry commentator, not a formal insider role. She holds positions at Genomics England and previously at The King's Fund — both of which interact with the UK health regulatory ecosystem — but neither gives her a direct line into MHRA decision-making. She was honoured with an OBE for contributions to life sciences, suggesting she operates at senior levels of the UK health establishment where informal networking with regulators is commonplace across the industry. Important caveat: Informal relationships between senior industry figures and regulators are rarely documented publicly. If you have a specific regulatory decision or conflict of interest concern in mind, the appropriate routes to investigate further would be: The MHRA's published registers of interests at gov.uk A Freedom of Information (FOI) request to the MHRA The MHRA's expert advisory group membership lists, which are publicly available Is there a specific context or concern driving this question? That might help me give you a more targeted answer. x.com/d_stock07734/s…

@jstrattman It will and should work great. First, NWBO's maturation protocols can make DCs produce more anti-tumor immune boosting cytokines. Second, peptides derived from the specific antigens can be fully uptaken and cross-presented by DCs with $NWBO's core DC vaccine technology.

@d_stock07734 Grok: Replacing Provenge w/ NWBO DCVax-Prostate (PSMA-loaded autologous DC vaccine) + IL-7 could be better. Early data: ~38.7 mo median OS & 64% 3-yr survival vs Provenge's ~25.8 mo & ~34%. PSMA is a strong target; +IL-7's T-cell boost might drive stronger responses.

$NWBO Dr. Mac Cheever was on the SAB of $NWBO. He was once involved in a trial on using the combination of Provenge with CYT107 to treat advanced prostate cancer. Note CYT107 can significantly increase the number of CD4 and CD8 t cells. What would happen to those cancer patients if Provenge were replaced with the DC vaccine developed by $NWBO? CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer clinicaltrials.gov/study/NCT01881… IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) pmc.ncbi.nlm.nih.gov/articles/PMC84… onlinelibrary.wiley.com/doi/10.1111/j.…

@ThomasOwenMcCa1 @KatStryker111 @kshaughnessy2 @NorthwestBio @LisainNJUSA @ElvirPons @nytimes @ABC @nymagPR @TheLastWord Griffin gave $125 million to the University of Chicago in 2017. It is true that everything and everyone can be bought for a price. economics.uchicago.edu/directory/john…

#ThisDidntAgeWell… ⁦@KatStryker111⁩ ⁦@kshaughnessy2⁩ ⁦@NorthwestBio⁩ ⁦@LisainNJUSA⁩ ⁦@ElvirPons⁩ ⁦@nytimes⁩ ⁦@ABC⁩ ⁦@nymagPR⁩ ⁦@TheLastWord⁩

@CscottLawyer @LeahDavis199340 Just: “we do not comment on the regulatory review process or their deliberations or our interactions with them”

@jstrattman @LeahDavis199340 $NWBO Did the company tell you whether they considered CHM issuing a CHM Letter regarding the DCVax-L MAA to be a material event?

$NWBO The thesis here is simple. If management had zero confidence in approval, they wouldn’t be expanding facilities and hiring aggressively. Capital moves signal expectations.

@CscottLawyer @LeahDavis199340 The company confirmed to me directly that a material event that would require an announcement is a denial or approval of the application and they will not disclose whether or not they continue to receive RFIs and questions.

@LeahDavis199340 $NWBO Why didn't NWBO issue an 8-K after the second CHM meeting on November 27-28, 2025? The CHM did one of 3 things: 1. Recommended approval of DCVax-L MAA; 2. Issued 2nd RFI to NWBO; or 3. Issued CHM Letter provisionally recommending rejection of DCVax-L MAA.